Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | BHMT | Q93088 | 4/20 | 0.40 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.37 |
| ▸ | GABRE | P78334 | 2/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19193551 | 1.00 | RNPEP (0.42) | RNPEPBHMTBHMT2ANPEPENPEP | |
| SCHEMBL13778624 | 1.00 | RNPEP (0.42) | RNPEPBHMTBHMT2ANPEPENPEP | |
| SCHEMBL23897837 | 0.88 | FOLH1 (0.42) | RNPEPBHMTBHMT2ANPEPENPEP | |
| SCHEMBL22387078 | 0.83 | RNPEP (0.48) | RNPEPBHMTBHMT2ANPEPENPEP | |
| SCHEMBL21345285 | 0.82 | RNPEP (0.38) | RNPEPBHMTBHMT2ANPEPENPEP | |
| Racemethionine SCHEMBL8347087 | 0.80 | BHMT (0.55) | RNPEPBHMTBHMT2NOS2NOS3 | |
| Methionine SCHEMBL6754482 | 0.80 | BHMT (0.55) | RNPEPBHMTBHMT2NOS2NOS3 | |
| SCHEMBL20792012 | 0.79 | GABRP (0.36) | BHMTBHMT2ANPEPGABRPGABRD | |
| Racemethionine SCHEMBL10527505 | 0.78 | BHMT (0.53) | RNPEPBHMTBHMT2NOS2NOS3 | |
| Methionine SCHEMBL10527521 | 0.78 | BHMT (0.53) | RNPEPBHMTBHMT2NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365577-A1 | Photodynamic Therapy and Diagnosis | RMW CHO GROUP LIMITED (HK) | 2023-11-16 | — | — | US | disclosed |
| WO-2023086557-A1 | NUCLEOSIDES FOR THE TREATMENT OF DNA VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022174179-A9 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| US-11406642-B2 | DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases | MITOCHON PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-11197882-B2 | — | — | 2021-12-14 | — | — | US | disclosed |
| US-11147826-B2 | — | — | 2021-10-19 | — | — | US | disclosed |
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-07 | — | — | US | disclosed |
| US-20210252033-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-19 | — | — | US | disclosed |
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8354383-B2 | 6,11-bridged biaryl macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8273720-B2 | 6,11-bicyclolides: bridged biaryl macrolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120122943-A1 | Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122943-A1 | Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20090270457-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | CYP2B6, ABCB11, CYP2D6 | RNPEP 869/4885BHMT 4334/4885BHMT2 4117/4885 |
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | ENTPD1, NME2, NME1 | RNPEP 1171/4885BHMT 258/4885BHMT2 589/4885 |
| US-20090270457-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | CYP2B6, ABCB11, CYP2D6 | RNPEP 869/4885BHMT 4334/4885BHMT2 4117/4885 |
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | RNPEP 1098/4885BHMT 4219/4885BHMT2 3716/4885 |
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, PRPF4, HPRT1 | RNPEP 671/4885BHMT 1949/4885BHMT2 2539/4885 |
| US-11147826-B2 | — | SNRPE, NME2, NME1 | RNPEP 1751/4885BHMT 409/4885BHMT2 707/4885 |
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | ENTPD1, NME2, NME1 | RNPEP 1171/4885BHMT 258/4885BHMT2 589/4885 |
| US-20210252033-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | TYMP, MTAP, DCTD | RNPEP 474/4885BHMT 51/4885BHMT2 77/4885 |
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | RNPEP 1098/4885BHMT 4219/4885BHMT2 3716/4885 |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | RNPEP 1250/4885BHMT 3955/4885BHMT2 3286/4885 |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | RNPEP 1098/4885BHMT 4219/4885BHMT2 3716/4885 |
| US-11197882-B2 | — | SNRPE, NME2, NME1 | RNPEP 1751/4885BHMT 409/4885BHMT2 707/4885 |
| US-11406642-B2 | DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases | SMN1; SMN2, MYLK2, WFS1 | RNPEP 3136/4885BHMT 2716/4885BHMT2 3089/4885 |
| US-20230365577-A1 | Photodynamic Therapy and Diagnosis | PPOX, PPIF, ALAD | RNPEP 807/4885BHMT 2814/4885BHMT2 1740/4885 |
| US-20120122943-A1 | Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents | MCL1, MYADM, BPGM | RNPEP 589/4885BHMT 248/4885BHMT2 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.